Brief CommunicationGefitinib in Patients with Brain Metastases from Non–Small-Cell Lung Cancer: Review of 15 Clinical Cases
References (34)
- et al.
Chemotherapy for brain metastases of lung cancer: a review
Ann Oncol
(1999) Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients
Semin Oncol
(2003)- et al.
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
Lung Cancer
(2003) - et al.
Dramatic effect of ZD1839 (Iressa) in a patient with advanced non-small-cell lung cancer and poor performance status
Lung Cancer
(2003) - et al.
Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients
Ann Oncol
(2004) - et al.
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
Ann Oncol
(2004) - et al.
Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier
Vasc Pharmacol
(2002) - et al.
The seed and soil hypothesis: vascularisation and brain metastases
Lancet Oncol
(2002) - et al.
Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer
Lung Cancer
(1998) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
Br Med J
(1995)
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis
J Clin Oncol
(1988)
Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced non-small cell lung carcinoma
Cancer
(2001)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
J Clin Oncol
(2003)
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFRtyrosine kinase inhibitor ZD1839 (Iressa)
Clin Cancer Res
(2002)
ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases
Br J Cancer
(2003)
A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain
Ann Oncol
(2003)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
J Natl Cancer Inst
(2000)
Cited by (0)
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cancer Information Group, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.
Copyright © 2004 Elsevier Inc. All rights reserved.